Enveric Biosciences ENVB a neuroscience company developing psychedelics and cannabinoids into mental health medicines, announced a collaboration with the University of Calgary’s Hotchkiss Brain Institute.
The parties will work on a clinical trial of EVM-101, a treatment based on oral psilocybin, for cancer-related distress.
According to a 2018 study, approximately 50% of cancer patients report clinical levels of psychological distress such as feelings of depressed mood, anxiety, demoralization, stress-induced clinical manifestations and reduced quality of life.
One of the goals of the trial is to identify which symptoms in cancer-related distress best respond to psychedelic-associated therapy.
Patient enrollment for the trial is expected to begin late in 2022 or in early 2023, according to Enveric, as the parties still need to send a regulatory submission to Health Canada to receive approval for the study.
While the trial will use psilocybin, a compound found in nature, the study design will employ proprietary psychiatry and psychotherapy-focused treatments for cancer patients with CRD.
© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Missed the first wave of cannabis investments? Don’t make that mistake again.
Experts believe cannabis stocks have found their floor and are now poised for unprecedented growth.
Join Benzinga PotProfits. Our in-house canna stock expert, Michael Berger, is on a mission to uncover the most promising cannabis stocks poised for growth, even in a dull market. He leaves no bud unturned to bring you the juiciest potential double-digit opportunities!
Just this year, the PotProfits portfolio has seen smoking-hot gains like:
- 47.10% with $GTBIF
- 40.23% with $TCNNF
- 21.50% with $VFF